The total costs of dementia are anticipated to be $818 billion in 2026, driven by quality-of-life losses for persons with dementia and care partners, according ...

The expanded indication makes risankizumab the first IL-23 inhibitor available for pediatric patients weighing under 40kg with plaque psoriasis or psoriatic arthritis, supported by phase 3 OptIMMize ...

Backed by data from the phase 3 SatraGO trials, satralizumab has the potential to offer patients a convenient, at-home treatment option.

The letter focuses exclusively on manufacturing control strategies for the biological component and contract manufacturing facility deficiencies. The Food and Drug Administration (FDA) has issued a ...

For ifosfamide, used to treat sarcomas, lymphomas and testicular cancers, some doctors are already meeting to decide who gets treated.

The new presentation is expected to provide an additional self-administration option for patients with polycythemia vera.

The FDA has approved an expanded indication for Zoryve (roflumilast) cream 0.3% to include plaque psoriasis in pediatric patients aged 2 years and older.

HealthDay News — Clover Hill Dairy is recalling all of its brand cheese over possible Listeria contamination tied to a ...

Transitioning from accelerated to traditional status, the FDA's decision expands eligibility for the first solid-tumor engineered T cell therapy to include adolescents aged 12 and older.

RelabotulinumtoxinA is a liquid neuromodulator designed to deliver rapid clinical improvement in glabellar and lateral canthal lines.

The chemotherapy-free combination reduced the risk of disease progression or death by up to 60% compared with standard ...

The table below evaluates treatment options for patients with thyroid eye disease, comparing Tepezza ® (teprotumumab-trbw) and Lumvoa ™ (veligrotug-vvze). Feature/Clinical Parameter Tepezza ® ...